IN2014MN00937A - - Google Patents

Info

Publication number
IN2014MN00937A
IN2014MN00937A IN937MUN2014A IN2014MN00937A IN 2014MN00937 A IN2014MN00937 A IN 2014MN00937A IN 937MUN2014 A IN937MUN2014 A IN 937MUN2014A IN 2014MN00937 A IN2014MN00937 A IN 2014MN00937A
Authority
IN
India
Prior art keywords
carrier
free radicals
damage caused
drug
antioxidant
Prior art date
Application number
Inventor
Chia Hung Chen
Chau Hui Wang
John son LIN
Tieh Hsiung CHIU
jing yi Chen
Pi Hung LIAO
Chia Chi SU
Wei Chuan Liao
Original Assignee
Original Biomedicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Original Biomedicals Co Ltd filed Critical Original Biomedicals Co Ltd
Publication of IN2014MN00937A publication Critical patent/IN2014MN00937A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Abstract

A pharmaceutical composition used for reducing the damage caused by free radicals is disclosed. The composition comprises at least a metal or its ions at least a drug or an antioxidant that is carrier protected/modified and a drug carrier. Said carrier helps to preserve the anti oxidative activity and hence prevents the decrease of the effect of the antioxidant against free radicals produced in the environment or body fluids and prolongs protection and may be used for reducing damage caused by radiation and adverse effects induced by chemotherapeutic drugs.
IN937MUN2014 2012-11-22 2012-11-22 IN2014MN00937A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/085066 WO2014079020A1 (en) 2012-11-22 2012-11-22 Pharmaceutical composition used for reducing damage caused by free radicals

Publications (1)

Publication Number Publication Date
IN2014MN00937A true IN2014MN00937A (en) 2015-09-04

Family

ID=50775402

Family Applications (1)

Application Number Title Priority Date Filing Date
IN937MUN2014 IN2014MN00937A (en) 2012-11-22 2012-11-22

Country Status (11)

Country Link
US (1) US9700623B2 (en)
EP (1) EP2922573B1 (en)
JP (1) JP5920955B2 (en)
KR (1) KR101730057B1 (en)
CN (1) CN104114188A (en)
AU (1) AU2012394378B2 (en)
BR (1) BR112014013185A2 (en)
CA (1) CA2851130C (en)
IL (1) IL232938B (en)
IN (1) IN2014MN00937A (en)
WO (1) WO2014079020A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102336699B1 (en) * 2015-02-23 2021-12-08 주식회사 파마리서치 Agent for inhibiting decomposition of hyaluronic acid comprising sodium 2-mercaptoethane sulfonate, and the composition comprising the same
KR102329495B1 (en) * 2015-02-23 2021-11-24 주식회사 파마리서치 Biodegradable polymer for administrating to a living body or for cosmetic surgery containing sodium 2-mercaptoethane sulfonate as an osmotic agent
CN106267223A (en) * 2015-05-11 2017-01-04 华东理工大学 A kind of target function material based on oxygen-derived free radicals and application thereof
CN110200941B (en) * 2019-06-24 2020-05-15 苏州大学 Radiation protection nano-medicine acting on small intestine and preparation method thereof
WO2021261355A1 (en) * 2020-06-22 2021-12-30 凸版印刷株式会社 Gel composition and production method therefor, and three-dimensional tissue body and production method therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03184922A (en) * 1989-12-14 1991-08-12 Pola Chem Ind Inc Skin drug for external use
JPWO2006033412A1 (en) * 2004-09-24 2008-05-15 株式会社林原生物化学研究所 Radiation damage reducing agent
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
KR100752990B1 (en) * 2006-08-02 2007-08-30 주식회사 대웅 Compositions for preventing or treating skin diseases comprising nanoliposomes and natural extracts
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology
GB0911002D0 (en) * 2009-06-25 2009-08-12 Univ Leuven Kath Metal organic framework synthesis
PL2552199T3 (en) * 2010-03-26 2015-11-30 Onconova Therapeutics Inc Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
WO2012058552A1 (en) * 2010-10-29 2012-05-03 Intezyne Technologies, Incorporated Iron stabilized polymer micelles for drug delivery applications
US20130071482A1 (en) * 2011-09-20 2013-03-21 The University Of Kentucky Research Foundation Block copolymer cross-linked nanoassemblies as modular delivery vehicles
US8785569B2 (en) * 2011-11-22 2014-07-22 Original Biomedicals Co., Ltd. Drug carrier with chelating complex micelles and the application thereof
TWI568453B (en) * 2011-11-22 2017-02-01 原創生醫股份有限公司 A drug carrier with chelating complex micelles and the application thereof

Also Published As

Publication number Publication date
AU2012394378A1 (en) 2014-06-12
JP2015510503A (en) 2015-04-09
EP2922573A1 (en) 2015-09-30
US9700623B2 (en) 2017-07-11
IL232938B (en) 2018-04-30
BR112014013185A2 (en) 2017-06-13
CA2851130C (en) 2019-10-01
IL232938A0 (en) 2014-07-31
AU2012394378B2 (en) 2016-06-02
KR20140097122A (en) 2014-08-06
EP2922573A4 (en) 2016-07-20
CN104114188A (en) 2014-10-22
JP5920955B2 (en) 2016-05-24
EP2922573B1 (en) 2018-11-14
US20150290321A1 (en) 2015-10-15
CA2851130A1 (en) 2014-05-22
KR101730057B1 (en) 2017-04-25
WO2014079020A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12016501015A1 (en) Combinations of histone deacetylase inhibitors and immunomodulatory drugs
BR112015011830A2 (en) compounds and their methods of use
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020003174A (en) Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer.
EP3031826A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
MX2015005963A (en) Heterocyclic glutaminase inhibitors.
MX2015013948A (en) Therapeutic uses of empagliflozin.
IN2014MN00937A (en)
IN2014DN10670A (en)
CL2015000897A1 (en) Pharmaceutical composition containing an oxygen carrier based on hemoglobin for the treatment of cancer targeting and prevention of cancer recurrence.
BR112015026238A2 (en) cancer treatment with dihydropyrazine pyrazines
MX2016001136A (en) Oxoquinazolinyl-butanamide derivatives.
PH12014501140A1 (en) Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder
TN2015000255A1 (en) Chitin or derivatives thereof for the prevention and/or treatment of parasitoses
MX2015000485A (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine.
MX366140B (en) Piperidine urea derivatives.
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations
EP2962693A4 (en) Pharmaceutical composition for prevention and/or treatment of cancer
EA201201483A1 (en) METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC SUBSTANCES
EA201690874A1 (en) PREVENTING ABUSE OF GRANULATED MEDICINAL FORMS WITH IMMEDIATE RELIEF
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
MX363378B (en) Nanoparticulate compositions and formulations of piperazine compounds.
WO2013157889A9 (en) Use of a novel aminopyridine derivative to prevent or treat cancer
PL405129A1 (en) New peptidomimetics with antiangiogenic activity